X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11370) 11370
Book Review (1983) 1983
Publication (377) 377
Newsletter (173) 173
Book / eBook (143) 143
Newspaper Article (100) 100
Book Chapter (87) 87
Magazine Article (34) 34
Conference Proceeding (23) 23
Dissertation (4) 4
Report (4) 4
Government Document (3) 3
Reference (3) 3
Trade Publication Article (3) 3
Data Set (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9834) 9834
humans (8626) 8626
male (5001) 5001
female (4880) 4880
adult (3444) 3444
middle aged (3158) 3158
anesthesiology (2585) 2585
animals (2332) 2332
neuromuscular agents - administration & dosage (2069) 2069
aged (1919) 1919
botulinum toxins, type a - administration & dosage (1873) 1873
abridged index medicus (1469) 1469
anesthesia (1420) 1420
time factors (1353) 1353
treatment outcome (1337) 1337
neuromuscular agents - therapeutic use (1310) 1310
neuromuscular nondepolarizing agents - administration & dosage (1257) 1257
adolescent (1242) 1242
neuromuscular junction - drug effects (1190) 1190
botulinum toxins, type a - therapeutic use (1157) 1157
neuromuscular blocking agents (1133) 1133
surgery (1108) 1108
neuromuscular blockade (1092) 1092
dose-response relationship, drug (1085) 1085
child (1032) 1032
botulinum toxin (1002) 1002
neurosciences (885) 885
prospective studies (879) 879
clinical neurology (853) 853
rats (844) 844
neuromuscular nondepolarizing agents - pharmacology (777) 777
vecuronium (752) 752
injections, intramuscular (741) 741
medicine & public health (741) 741
pediatrics (731) 731
child, preschool (729) 729
pharmacology & pharmacy (701) 701
rocuronium (672) 672
care and treatment (670) 670
double-blind method (645) 645
research (644) 644
atracurium (643) 643
muscle contraction - drug effects (634) 634
double-blind (619) 619
neuromuscular blocking agents - administration & dosage (590) 590
analysis (567) 567
androstanols - administration & dosage (562) 562
anesthesia, general (558) 558
neuromuscular agents - adverse effects (549) 549
injections (542) 542
young adult (536) 536
children (515) 515
neuromuscular diseases (508) 508
neuromuscular blocking agents - pharmacology (500) 500
intubation, intratracheal (499) 499
electric stimulation (498) 498
retrospective studies (493) 493
electromyography (488) 488
succinylcholine (483) 483
botulinum toxins, type a - adverse effects (479) 479
health aspects (476) 476
management (472) 472
infant (466) 466
mice (462) 462
anesthesia recovery period (447) 447
propofol (447) 447
neurology (439) 439
neuromuscular nondepolarizing agents - adverse effects (439) 439
dosage and administration (431) 431
aged, 80 and over (420) 420
neuromuscular junction - physiology (410) 410
pain (409) 409
follow-up studies (401) 401
blood pressure - drug effects (384) 384
synaptic transmission - drug effects (380) 380
muscle, skeletal - drug effects (376) 376
pharmacokinetics (373) 373
anesthetics, intravenous - administration & dosage (372) 372
muscles (372) 372
heart rate - drug effects (354) 354
atracurium - administration & dosage (351) 351
drug interactions (349) 349
efficacy (349) 349
patients (349) 349
neuromuscular blockade - methods (348) 348
drug therapy (341) 341
pain medicine (341) 341
in vitro techniques (340) 340
safety (332) 332
dermatology (330) 330
intubation (330) 330
risk factors (330) 330
intubation, intratracheal - methods (329) 329
critical care medicine (327) 327
succinylcholine - administration & dosage (327) 327
pancuronium (326) 326
androstanols - pharmacology (323) 323
neuromuscular block (323) 323
neuromuscular nondepolarizing agents - antagonists & inhibitors (323) 323
vecuronium bromide - administration & dosage (322) 322
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (115) 115
Holland Bloorview Kids Rehabilitation - Stacks (8) 8
Collection Dvlpm't (Acquisitions) - Closed Orders (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
UTL at Downsview - May be requested (4) 4
Providence Healthcare - Stacks (3) 3
UofT at Scarborough - Stacks (2) 2
Credit Valley Hospital - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Holland Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10948) 10948
French (222) 222
German (176) 176
Spanish (128) 128
Japanese (109) 109
Russian (107) 107
Polish (30) 30
Chinese (23) 23
Italian (22) 22
Korean (22) 22
Danish (21) 21
Portuguese (18) 18
Czech (10) 10
Dutch (10) 10
Swedish (9) 9
Turkish (9) 9
Croatian (6) 6
Norwegian (6) 6
Romanian (6) 6
Bulgarian (4) 4
Finnish (4) 4
Serbian (3) 3
Hebrew (2) 2
Slovak (2) 2
Arabic (1) 1
Bosnian (1) 1
Hungarian (1) 1
Lithuanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Pediatrics, ISSN 0031-4005, 08/2014, Volume 134, Issue 2, pp. e620 - e638
Guidance from the American Academy of Pediatrics (AAP) for the use of palivizumab prophylaxis against respiratory syncytial virus (RSV) was first published in... 
Infants and young children | Palivizumab | Respiratory syncytial virus | RSV | Congenital heart disease | Chronic lung disease | Bronchiolitis | COST-EFFECTIVENESS ANALYSIS | UNITED-STATES | palivizumab | PREMATURE-INFANTS | BRONCHIOLITIS-ASSOCIATED HOSPITALIZATIONS | chronic lung disease | bronchiolitis | SOLID-ORGAN TRANSPLANT | INVESTIGATORS COLLABORATIVE NETWORK | CELL TRANSPLANT RECIPIENTS | congenital heart disease | HUMANIZED MONOCLONAL-ANTIBODY | PEDIATRICS | NEONATAL INTENSIVE-CARE | respiratory syncytial virus | infants and young children | RSV PROPHYLAXIS | Respiratory Syncytial Virus Infections - epidemiology | Antiviral Agents - pharmacokinetics | Respiratory Syncytial Virus Infections - ethnology | Humans | Child, Preschool | Hospitalization - statistics & numerical data | Infant | Indians, North American - statistics & numerical data | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Respiratory Syncytial Virus Infections - prevention & control | Respiratory Sounds | Seasons | Antibodies, Monoclonal, Humanized - therapeutic use | Antiviral Agents - therapeutic use | Comorbidity | Risk Factors | Down Syndrome - epidemiology | Injections, Intramuscular | Cystic Fibrosis - epidemiology | Antiviral Agents - administration & dosage | Gestational Age | Infant, Premature | Immunocompromised Host | Neuromuscular Diseases - epidemiology | Care and treatment | Respiratory syncytial virus infection | Dosage and administration | Infants | Children | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
European Urology, ISSN 0302-2838, 2013, Volume 64, Issue 2, pp. 249 - 256
Abstract Background Overactive bladder (OAB) syndrome with urinary incontinence (UI) is prevalent in the population and impairs health-related quality of life... 
Urology | Urinary incontinence | OnabotulinumtoxinA | Overactive bladder | Botulinum toxin | POPULATION | EFFICACY | TRACT SYMPTOMS | BOTULINUM-TOXIN | DOSE-RANGING TRIAL | WOMEN | IMPACT | UROLOGY & NEPHROLOGY | QUESTIONNAIRE | ANTICHOLINERGIC THERAPY | United States | Humans | Middle Aged | Urodynamics - drug effects | Male | Neuromuscular Agents - therapeutic use | Botulinum Toxins, Type A - administration & dosage | Urinary Bladder - innervation | Botulinum Toxins, Type A - therapeutic use | Urinary Bladder, Overactive - drug therapy | Urinary Bladder, Overactive - psychology | Time Factors | Urinary Bladder, Overactive - physiopathology | Urination - drug effects | Neuromuscular Agents - administration & dosage | Adult | Female | Surveys and Questionnaires | Urinary Incontinence, Urge - drug therapy | Urinary Incontinence, Urge - physiopathology | Cholinergic Antagonists - therapeutic use | Botulinum Toxins, Type A - adverse effects | Urinary Bladder, Overactive - diagnosis | Double-Blind Method | Europe | Treatment Outcome | Urinary Incontinence, Urge - psychology | Injections, Intramuscular | Urinary Incontinence, Urge - diagnosis | Neuromuscular Agents - adverse effects | Quality of Life | Urinary Bladder - physiopathology | Urinary Bladder - drug effects | Aged | Clinical trials | Incontinence | Care and treatment | Index Medicus
Journal Article
Journal Article
Critical Care, ISSN 1364-8535, 04/2015, Volume 19, Issue 1, pp. 134 - 134
Journal Article
Intensive Care Medicine, ISSN 0342-4642, 3/2017, Volume 43, Issue 3, pp. 408 - 418
Journal Article
European Urology, ISSN 0302-2838, 2012, Volume 62, Issue 3, pp. 507 - 514
Abstract Background Emerging data suggest botulinum toxin is an effective treatment for detrusor overactivity (DO), but large studies confirming efficacy and... 
Urology | Incontinence | Detrusor overactivity | Botulinum toxin | Randomised trial | Idiopathic | ANTIMUSCARINIC AGENT | EFFICACY | SAFETY | TOLTERODINE | SOLIFENACIN | URGE URINARY-INCONTINENCE | TOLERABILITY | ANTICHOLINERGIC DRUGS | UROLOGY & NEPHROLOGY | BLADDER | Multivariate Analysis | Humans | Middle Aged | Urodynamics - drug effects | Neuromuscular Agents - therapeutic use | Botulinum Toxins, Type A - administration & dosage | Recovery of Function | Botulinum Toxins, Type A - therapeutic use | Urinary Bladder, Overactive - drug therapy | Time Factors | Urinary Bladder, Overactive - physiopathology | Neuromuscular Agents - administration & dosage | Female | Urinary Incontinence, Urge - drug therapy | Urinary Incontinence, Urge - physiopathology | Odds Ratio | Botulinum Toxins, Type A - adverse effects | Urinary Bladder, Overactive - complications | Urinary Bladder, Overactive - diagnosis | Double-Blind Method | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Linear Models | Treatment Outcome | United Kingdom | Chi-Square Distribution | Urinary Catheterization | Urinary Tract Infections - etiology | Neuromuscular Agents - adverse effects | Urinary Bladder - physiopathology | Urinary Bladder - drug effects | Aged | Urinary Incontinence, Urge - etiology | Administration, Intravesical | Clinical trials | Index Medicus
Journal Article
Anesthesiology, ISSN 0003-3022, 08/2007, Volume 107, Issue 2, pp. 245 - 252
Journal Article